Ben Maynor, PhD

Dr. Ben Maynor has advised AnelleO, Inc. for over five years on matters concerning product development. He is an experienced drug developer with a proven record of building and leading R&D and Chemistry, Manufacturing, and Controls (CMC) organizations within pharmaceutical and biotechnology companies. Most recently, Dr. Maynor was the Senior Vice President of CMC at Orna Therapeutics, where he was responsible for Orna’s circular RNA/lipid nanoparticle technology and products. Prior to joining Orna, he was the Senior Vice President, R&D at Liquidia Technologies, where he co-invented Liquidia’s platform particle technology and led pipeline product development. At Liquidia, Dr. Maynor initiated new technology initiatives and product development programs in ophthalmology, pain management, pulmonary hypertension, infectious disease, and vaccines. Ben received his Ph.D. in Chemistry from Duke University, where he focused on nanotechnology and physical chemistry. His postdoctoral research was conducted at UNC-Chapel Hill, where he co-developed the PRINT particle technology (with Joseph DeSimone, PhD). Ben received his undergraduate degree in Chemistry from Harvard University. After his postdoc, Dr. Maynor transitioned to the founding team of Liquidia Technologies.